keyword
MENU ▼
Read by QxMD icon Read
search

Pancreatic carcinoma

keyword
https://www.readbyqxmd.com/read/28534950/microrna%C3%A2-296-targets-akt2-in-pancreatic-cancer-and-functions-as-a-potential-tumor-suppressor
#1
Hailing Li, Jilin Li, Baolin Shi, Feng Chen
Although microRNA-296 (miR-296) has been studied in various types of human cancer, its expression, biological role and mechanism of action in pancreatic cancer remains to be elucidated. The aim of the current study was to investigate the expression level, possible roles and underlying molecular mechanisms of miR‑296 in pancreatic cancer. The present study revealed that miR‑296 is significantly downregulated in tissue from patients with pancreatic cancer and in human pancreatic carcinoma cell lines, when compared with matched healthy tissue and normal human pancreatic cell lines, respectively...
May 18, 2017: Molecular Medicine Reports
https://www.readbyqxmd.com/read/28534807/lobophorin-k-a-new-natural-product-with-cytotoxic-activity-produced-by-streptomyces-sp-m-207-associated-with-the-deep-sea-coral-lophelia-pertusa
#2
Alfredo F Braña, Aida Sarmiento-Vizcaíno, Miguel Osset, Ignacio Pérez-Victoria, Jesús Martín, Nuria de Pedro, Mercedes de la Cruz, Caridad Díaz, Francisca Vicente, Fernando Reyes, Luis A García, Gloria Blanco
The present article describes the isolation of a new natural product of the lobophorin family, designated as lobophorin K (1), from cultures of the marine actinobacteria Streptomyces sp. M-207, previously isolated from the cold-water coral Lophelia pertusa collected at 1800 m depth during an expedition to the submarine Avilés Canyon. Its structure was determined using a combination of spectroscopic techniques, mainly ESI-TOF MS and 1D and 2D NMR. This new natural product displayed cytotoxic activity against two human tumor cell lines, such as pancreatic carcinoma (MiaPaca-2) and breast adenocarcinoma (MCF-7)...
May 19, 2017: Marine Drugs
https://www.readbyqxmd.com/read/28533658/checkpoint-inhibitors-in-gastrointestinal-cancers-expectations-and-reality
#3
EDITORIAL
Hampig Raphael Kourie, Samer Tabchi, Marwan Ghosn
Immune checkpoint inhibitors represent revolutionary anti-cancer agents, being rapidly approved in different malignancies and settings. Gastrointestinal (GI) cancers represent a wide variety of tumors with specific characteristics and different responses to various therapeutic alternatives; while some are chemo-sensitive others are chemo-resistant and only respond to more aggressive cytotoxic regimens, targeted therapies or a combination of both. Preliminary results of immune checkpoint inhibitors in some GI cancers are promising, namely in hepatocellular carcinoma, anal cancers and microsatellite instability high colorectal cancers...
May 7, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28529742/intraductal-tubulopapillary-neoplasm-accompanied-by-invasive-carcinoma-of-the-pancreas-a-case-report-and-review-of-the-literature
#4
Li Niu, Zhigao Xu, Huan Liu, Hong Cao, Guifang Yang
Intraductal tubulopapillary neoplasms (ITPNs) are rare pancreatic neoplasms accounting for ~0.4% of pancreatic tumors. However, their clinicopathological characteristics have not been clearly determined and the number of available clinical studies on this type of tumor is limited at present. Due to the rare incidence of ITPN, diagnosis is often delayed. We herein present a unique case of a 38-year-old man who was diagnosed with ITPN accompanied with invasive carcinoma of the pancreas and underwent total pancreatectomy...
May 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28529741/pazopanib-induced-asymptomatic-radiological-acute-pancreatitis-a-case-report
#5
Iosune Baraibar, Almudena Quílez, Diego Salas, Marta Román, Christian Rolfo, José L Pérez-Gracia, Ignacio Gil-Bazo
The universal clinical use of multi-targeted tyrosine kinase inhibitors (TKIs) in patients diagnosed with advanced renal cell carcinoma (RCC) has significantly prolonged their estimated survival times and their quality of life. However, several adverse side-effects associated predominantly with the inhibition of the vascular endothelial growth factor receptor by these drugs may prove to be potentially life-threatening. One adverse event that is only rarely observed with the use of TKIs in this clinical setting is acute pancreatitis...
May 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28529740/copy-number-variation-and-protein-expression-of-dot1l-in-pancreatic-adenocarcinoma-as-a-potential-drug-target
#6
Heike Loeser, Dirk Waldschmidt, Fabian Kuetting, Carina Heydt, Thomas Zander, Patrick Plum, Hakan Alakus, Reinhard Buettner, Alexander Quaas
Adenocarcinoma of the pancreas has a poor prognosis. At present, no relevant personalized targets have been identified. Sequencing studies have implicated gene alterations of disruptor of telomeric silencing 1 like histone lysine methyltransferase (DOT1L) in pancreatic adenocarcinoma. DOT1L is part of the histone modification system and catalyzes methylation of H3K79, which is crucial in cell signaling and DNA damage repair. DOT1L is considered to be a target of therapy in mixed lineage leukemia gene-deficient leukemia cases and a potential target in breast carcinoma...
May 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28522787/surgical-treatment-of-pancreatic-cystic-tumors
#7
Beata Jabłońska, Łukasz Braszczok, Weronika Szczęsny-Karczewska, Beata Dubiel-Braszczok, Paweł Lampe
The aim of this study was to assess short-term outcomes of surgical treatment of pancreatic cystic tumors (PCTs). MATERIAL AND METHODS: We retrospectively reviewed medical records of 46 patients (31 women and 15 men) who had undergone surgery for pancreatic cystic tumors in our department. RESULTS: Pancreatic cystic tumors were located within the pancreatic head (21), body (11), tail (13), and whole pancreas (1). The following surgical procedures were performed: pancreatoduodenectomy (20), central pancreatectomy (9), distal pancreatectomy (3), distal pancreatectomy with splenectomy (3), distal extended pancreatectomy with splenectomy (2), total pancreatectomy (1), duodenum preserving pancreatic head resection (1), local tumor resection (4), and other procedures (2)...
February 28, 2017: Polski Przeglad Chirurgiczny
https://www.readbyqxmd.com/read/28521422/clinical-outcomes-and-prognostic-factors-of-resected-pancreatic-neuroendocrine-neoplasms-a-single-center-experience-in-china
#8
Kaizhou Jin, Guopei Luo, Jin Xu, Bo Zhang, Chen Liu, Shunrong Ji, Liang Liu, Jiang Long, Quanxing Ni, Xianjun Yu
The aim of the present study was to investigate the clinical, pathological and prognostic characteristics of Chinese patients with resected pancreatic neuroendocrine neoplasms (p-NENs). Data from patients who were surgically treated and pathologically diagnosed with p-NENs at the Department of Pancreatic Oncology of the Fudan University Shanghai Cancer Center (Shanghai, China), between January 2003 and July 2015, were evaluated using univariate and multivariate analyses. A total of 162 patients with p-NENs met the criteria of the present study and were included in the analysis...
May 2017: Oncology Letters
https://www.readbyqxmd.com/read/28521313/amrubicin-monotherapy-for-patients-with-platinum-pretreated-non-gastrointestinal-non-pancreatic-extrapulmonary-neuroendocrine-carcinoma
#9
Takahiro Ebata, Tatsunori Shimoi, Tsukasa Ishiwata, Shunichiro Iwasawa, Seiko Bun, Mayu Yunokawa, Kan Yonemori, Yuichi Takiguchi, Kenji Tamura
OBJECTIVE: The aim of this study was to investigate the clinical usefulness of amrubicin therapy for patients with non-gastrointestinal (GI) non-pancreatic extrapulmonary neuroendocrine carcinoma (EP-NEC). METHODS: The medical records of patients from the 2 participating institutions were retrospectively reviewed. The eligibility criteria were: patients with non-GI non-pancreatic EP-NEC who received amrubicin monotherapy after platinum-based chemotherapy. Patients in whom the platinum-free interval (interval between the last day of platinum administration and the first subsequent documentation of disease progression) was 90 days or longer were classified into the platinum-sensitive group...
May 19, 2017: Oncology
https://www.readbyqxmd.com/read/28516310/natural-history-of-patients-followed-radiographically-with-mucinous-cysts-of-the-pancreas
#10
Linda M Pak, Michael I D'Angelica, Ronald P DeMatteo, T Peter Kingham, Vinod P Balachandran, William R Jarnagin, Peter J Allen
OBJECTIVE: The aim of this study was to evaluate the outcome of patients presumed to have mucinous cysts of the pancreas who were initially selected for radiographic surveillance. METHODS: Patients with a pancreatic cyst and a measured cyst fluid carcinoembryonic antigen (CEA) ≥192 ng/mL were included. Patients were stratified by those who underwent initial resection and those who were recommended for radiographic surveillance. The natural history of these two groups was examined...
May 17, 2017: Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract
https://www.readbyqxmd.com/read/28515362/insulin-supplementation-attenuates-cancer-induced-cardiomyopathy-and-slows-tumor-disease-progression
#11
James T Thackeray, Stefan Pietzsch, Britta Stapel, Melanie Ricke-Hoch, Chun-Wei Lee, Jens P Bankstahl, Michaela Scherr, Jörg Heineke, Gesine Scharf, Arash Haghikia, Frank M Bengel, Denise Hilfiker-Kleiner
Advanced cancer induces fundamental changes in metabolism and promotes cardiac atrophy and heart failure. We discovered systemic insulin deficiency in cachectic cancer patients. Similarly, mice with advanced B16F10 melanoma (B16F10-TM) or colon 26 carcinoma (C26-TM) displayed decreased systemic insulin associated with marked cardiac atrophy, metabolic impairment, and function. B16F10 and C26 tumors decrease systemic insulin via high glucose consumption, lowering pancreatic insulin production and producing insulin-degrading enzyme...
May 18, 2017: JCI Insight
https://www.readbyqxmd.com/read/28512284/improved-survival-in-patients-with-resected-pancreatic-carcinoma-using-postoperative-intensity-modulated-radiotherapy-and-regional-intra-arterial-infusion-chemotherapy
#12
Ningyi Ma, Zheng Wang, Jiandong Zhao, Jiang Long, Jin Xu, Zhigang Ren, Guoliang Jiang
BACKGROUND We assessed the role of adjuvant intensity-modulated radiotherapy (IMRT) in combination with chemotherapy for pancreatic carcinomas after curative resection and identified prognostic factors related to pancreatic carcinoma after multidisciplinary treatment strategies. MATERIAL AND METHODS Pancreatic carcinoma patients (n=61) who received adjuvant radiotherapy after resection (median dose, 50.4 Gy) between 2010 and 2016 were retrospectively identified. Sixty patients received chemotherapy, including concurrent chemoradiotherapy (CCRT), systemic chemotherapy, and regional intra-arterial infusion chemotherapy (RIAC)...
May 17, 2017: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/28511147/squamous-cell-carcinoma-of-the-pancreas-a-systematic-review-and-pooled-survival-analysis
#13
REVIEW
Ioannis Ntanasis-Stathopoulos, Diamantis I Tsilimigras, Despoina Georgiadou, Prodromos Kanavidis, Olga Riccioni, Charitini Salla, Theodora Psaltopoulou, Theodoros N Sergentanis
The diagnosis and treatment of squamous cell carcinoma of the pancreas pose dilemmas in the clinical practice. The present study was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Eligible articles were sought in MEDLINE up to 30th April 2016. A pooled Cox regression analysis was performed to evaluate factors potentially associated with overall survival (OS) and relapse-free survival (RFS). Fifty-four cases of pure squamous cell pancreatic carcinomas were identified in total...
May 13, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28507002/neuregulin-1-allosterically-enhances-the-anti-tumor-effects-of-the-non-competing-anti-her3-antibody-9f7-f11-by-increasing-its-binding-to-her3
#14
Christophe Le Clorennec, Hervé Bazin, Olivier Dubreuil, Christel Larbouret, Charline Ogier, Yassamine Lazrek, Veronique Garambois, Marie-Alix Poul, Philippe Mondon, Jean-Marc Barret, Gérard Mathis, Jean-François Prost, André Pèlegrin, Thierry Chardès
Exploratory clinical trials using therapeutic anti-HER3 antibodies strongly suggest that neuregulin (NRG1; HER3 ligand) expression at tumor sites is a predictive biomarker of anti-HER3 antibody efficacy in cancer. We hypothesized that in NRG1-expressing tumors, where the ligand is present before antibody treatment, anti-HER3 antibodies that do not compete with NRG1 for receptor binding have a higher receptor-neutralizing action than antibodies competing with the ligand for binding to HER3. Using time resolved-fluorescence energy transfer (TR-FRET), we demonstrated that in the presence of recombinant NRG1, binding of 9F7-F11 (a non-ligand competing anti-HER3 antibody) to HER3 is increased, whereas that of ligand-competing anti-HER3 antibodies (H4B-121, U3-1287, Ab#6, Mab205...
May 15, 2017: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/28501762/poorly-differentiated-gastro-entero-pancreatic-neuroendocrine-carcinomas-are-they-really-heterogeneous-insights-from-the-ffcd-gte-national-cohort
#15
T Walter, D Tougeron, E Baudin, K Le Malicot, T Lecomte, D Malka, O Hentic, S Manfredi, I Bonnet, R Guimbaud, R Coriat, C Lepère, C Desauw, A Thirot-Bidault, L Dahan, G Roquin, T Aparicio, J-L Legoux, C Lombard-Bohas, J-Y Scoazec, C Lepage, G Cadiot
BACKGROUND: Diagnosis and management of poorly differentiated gastro-entero-pancreatic (GEP) neuroendocrine carcinomas (NECs) remain challenging. Recent studies suggest prognostic heterogeneity. We designed within the French Group of Endocrine Tumours a prospective cohort to gain insight in the prognostic stratification and treatment of GEP-NEC. PATIENTS AND METHODS: All patients with a diagnosis of GEP-NEC between 1st January 2010 and 31st December 2013 could be included in this national cohort...
May 11, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28499761/cystadenoma-of-the-rete-testis-in-a-patient-with-von-hippel-lindau-disease
#16
Jacob Lewis, David Thiel, Gregory Broderick, Candice Bolan
Von-Hippel Lindau (VHL) disease is a rare, inherited multicystic disorder that is characterized by several benign and malignant neoplasms (1). Classically, the disease manifests itself in a broad spectrum including: renal cell carcinomas, intracranial and spinal hemangioblastomas, endolymphatic sac tumors, renal and pancreatic cysts, and pheochromocytomas. Another important, but commonly forgotten manifestation is the cystadenoma of the rete testis.
May 9, 2017: Urology
https://www.readbyqxmd.com/read/28499439/the-role-of-tgf-%C3%AE-and-its-crosstalk-with-rac1-rac1b-signaling-in-breast-and-pancreas-carcinoma
#17
REVIEW
Catharina Melzer, Ralf Hass, Juliane von der Ohe, Hendrik Lehnert, Hendrik Ungefroren
This article focusses on the role of TGF-β and its signaling crosstalk with the RHO family GTPases RAC1 and RAC1b in the progression of breast and pancreatic carcinoma. The aggressive nature of these tumor types is mainly due to metastatic dissemination. Metastasis is facilitated by desmoplasia, a peculiar tumor microenvironment and the ability of the tumor cells to undergo epithelial-mesenchymal transition (EMT) and to adopt a motile and invasive phenotype. These processes are controlled entirely or in part by TGF-β and the small RHO GTPase RAC1 with both proteins acting as tumor promoters in late-stage cancers...
May 12, 2017: Cell Communication and Signaling: CCS
https://www.readbyqxmd.com/read/28487979/trail-mutant-membrane-penetrating-peptide-alike-mur6-tr-enhances-the-antitumor-effects-of-trail-in-pancreatic-carcinoma-both-in-vitro-and-in-vivo
#18
Lei Sun, Chen Chen, Aijing Zhu, Ying Huang, Hong Zhu, Cheng Yi
To remedy the drug resistance of natural tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and enhance its antitumor effects, we prepared a type of TRAIL mutant membrane penetrating peptide alike (TMPPA)‑TRAIL mutant R6 (MuR6-TR) by mutating the N‑terminal of the soluble TRAIL gene sequence. The expressed MuR6‑TR protein was purified to treat pancreatic carcinoma cell lines BxPC‑3 and PANC‑1. The inhibitory effects on the proliferation of BxPC‑3 and PANC‑1 cells was assessed with CCK‑8 assay and compared with natural TRAIL...
June 2017: International Journal of Molecular Medicine
https://www.readbyqxmd.com/read/28487737/insurance-status-is-related-to-receipt-of-therapy-and-survival-in-patients-with-early-stage-pancreatic-exocrine-carcinoma
#19
Emily Boevers, Bradley D McDowell, Sarah L Mott, Anna M Button, Charles F Lynch
Objectives. The study objective was to determine how insurance status relates to treatment receipt and overall survival for patients with early-stage pancreatic exocrine carcinoma. Methods. SEER data were evaluated for 17,234 patients diagnosed with Stage I/II pancreatic exocrine carcinoma. Multivariate regression models controlled for personal characteristics to determine whether insurance status was independently associated with overall survival and receipt of radiation/surgery. Results. Odds of receiving radiation were 1...
2017: Journal of Cancer Epidemiology
https://www.readbyqxmd.com/read/28487490/differentiation-of-pancreatic-neuroendocrine-carcinoma-from-pancreatic-ductal-adenocarcinoma-using-magnetic-resonance-imaging-the-value-of-contrast-enhanced-and-diffusion-weighted-imaging
#20
Chuangen Guo, Xiao Chen, Zhongqiu Wang, Wenbo Xiao, Qidong Wang, Ke Sun, Xiaoling Zhuge
Pancreatic neuroendocrine carcinoma (PNEC) is often misdiagnosed as pancreatic ductal adenocarcinoma (PDAC). This retrospective study differentiated PNEC from PDAC using magnetic resonance imaging (MRI), including contrast-enhanced (CE) and diffusion-weighted imaging (DWI). Clinical data and MRI findings, including the T1/T2 signal, tumor boundary, size, enhancement degree, and apparent diffusion coefficient (ADC), were compared between 37 PDACs and 13 PNECs. Boundaries were more poorly defined in PDAC than PNEC (97...
April 21, 2017: Oncotarget
keyword
keyword
12401
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"